Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAV-AQP1
- Development stage
- Phase 1
- Lead developer
- MeiraGTx
- Modality
- Gene Therapies
- Administration
- Intraglandular, Intraductal
01
Overview
AAV-AQP1 is a gene therapy being developed for the treatment of xerostomia (dry mouth). It uses adeno-associated virus (AAV) to deliver the human aquaporin-1 (AQP1) gene to salivary glands that have been damaged by radiation therapy or affected by autoimmune diseases such as Sjögren's syndrome. The therapy is designed to increase water conduction in damaged salivary glands by introducing a water conducting channel, thereby restoring fluid secretion and alleviating symptoms of dry mouth. The mechanism involves transcellular movement of fluid via AQP1 proteins, which appear to be decreased in patients with xerostomia.
- Other names
- AAV AQP1
02
Targets
AQP1 (Aquaporin-1)
Beyond the preview
Go deeper on AAV-AQP1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AAV-AQP1.